Genpharm Services announced today that it has entered into a multiyear agreement with Aegerion Pharmaceuticals for the commercialization of Juxtapid® (Lomitapide), their FDA approved Orphan Drug for the treatment of Homozygous Familial Hypercholesterlemia (HoFH). The scope of the agreement covers the Levant region.
Homozygous familial hypercholesterolemia (HoFH) is the most severe form of familial hypercholesterolemia. HoFH is caused by genetic defects inherited from both parents that affect the function of the low-density lipoprotein (LDL) receptor, the receptor responsible for removing LDL-C cholesterol (bad cholesterol) from the body. HoFH is characterized by extremely high levels of LDL cholesterol (LDL-C).
Juxtapid® (Lomitapide) is an FDA approved adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH).
“Adding Lomitapide to our portfolio is in line with our strategy to bring important therapeutic advances to the region, for patients suffering from genetic disease. HoFH is prevalent in the region. Nevertheless, awareness is still relatively low. We look forward to working closely with healthcare professionals and regulators to raise public awareness, improve HoFH diagnosis and make Juxtapid® available in our region”, says Karim Smaira CEO of Genpharm Services.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases.
Genpharm Services is a pharmaceutical marketing company, based in the Dubai Biotechnology and Research Park, UAE. Through Evidence based medicine, Genpharm provides healthcare organizations with innovative therapeutic solutions, in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions, in the Middle East and North Africa Region.